Ticker brief
RHHBY ROCHE HOLDINGS LTD-SPONS ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$53.04
1 day
+5.4%
14 days
+6.6%
mkt cap
·
signals 14d
32
authors 14d
11
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-07-02 · now +0.37 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | +1.35 | 8 | +0.02 |
| @OzmosiHealth | C | · | 8 | +0.47 |
| @Quantumup1 | C | -1.95 | 5 | +0.00 |
| @PersimmonTI | A | -0.32 | 2 | +0.00 |
| @CrweWorld | C | · | 2 | +0.45 |
| @EmmanuelInvest | C | -1.12 | 2 | +0.58 |
| @FierceBiotech | A | -0.09 | 1 | +0.00 |
| @AponiaAnalytics | B | +0.89 | 1 | +0.30 |
| @LiveSquawk | B | · | 1 | +0.50 |
| @fwpharma | B | +0.22 | 1 | +0.45 |
| @BiopharmIQ | B | · | 1 | +0.20 |
Recent signals30of 32 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @bioinvestor24 | -0.10 | Author discusses ABBV/APGE negotiations including AbbVie starting with a $10B proposal and no other offers. | — | tweet ↗ |
| 2026-07-02 | @BiopharmIQ | +0.20 | Biotech midday mover list with catalysts and percentage moves. | — | tweet ↗ |
| 2026-07-02 | @OzmosiHealth | +0.45 | Roche divarasib shows superiority in head-to-head phase III trial. | — | tweet ↗ |
| 2026-07-02 | @OzmosiHealth | +0.45 | Roche divarasib shows superiority in head-to-head phase III trial. | — | tweet ↗ |
| 2026-07-02 | @OzmosiHealth | +0.45 | Genentech divarasib shows superiority in Phase III NSCLC trial. | — | tweet ↗ |
| 2026-07-02 | @OzmosiHealth | +0.45 | Genentech divarasib shows superiority in Phase III NSCLC trial. | — | tweet ↗ |
| 2026-07-02 | @fwpharma | +0.45 | Roche's divarasib beat KRAS G12C rivals in a late-stage NSCLC study. | — | tweet ↗ |
| 2026-07-02 | @EmmanuelInvest | +0.55 | Roche announced positive Phase III divarasib results in KRAS G12C lung cancer. | — | tweet ↗ |
| 2026-07-02 | @CrweWorld | +0.40 | Roche's divarasib showed superiority in a head-to-head phase III lung cancer trial. | — | tweet ↗ |
| 2026-07-01 | @EmmanuelInvest | +0.60 | Roche divarasib outperformed Amgen and BMS rival therapies in Phase 3 trial. | +5.4% | tweet ↗ |
| 2026-07-01 | @LiveSquawk | +0.50 | Roche lung-cancer drug candidate beat existing therapies in late-stage trial. | +5.4% | tweet ↗ |
| 2026-07-01 | @bioinvestor24 | -0.10 | Expects favorable VKTX tolerability and suggests leaked 21-week data may explain strength. | +5.4% | tweet ↗ |
| 2026-07-01 | @Quantumup1 | +0.00 | Cantor reiterates VKTX Overweight with $100 target and positive setup into 3Q26 data. | +5.4% | tweet ↗ |
| 2026-06-30 | @bioinvestor24 | -0.35 | Says obesity competition is inferior and Lilly faces weak rivals. | +3.3% | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.50 | FDA grants Priority Review to Roche's Enspryng for thyroid eye disease. | +3.3% | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.50 | FDA grants Priority Review to Roche's Enspryng for thyroid eye disease. | +3.3% | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.50 | FDA grants Priority Review to Genentech's Enspryng application for thyroid eye disease. | +3.3% | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.50 | FDA grants Priority Review to Genentech's Enspryng application for thyroid eye disease. | +3.3% | tweet ↗ |
| 2026-06-30 | @CrweWorld | +0.50 | FDA grants Priority Review to Roche's Enspryng for thyroid eye disease. | +3.3% | tweet ↗ |
| 2026-06-29 | @bioinvestor24 | -0.35 | Criticizes Roche presentation and draws parallels to NVO and PFE GLP1 errors. | +0.9% | tweet ↗ |
| 2026-06-29 | @AponiaAnalytics | +0.30 | Roche launched AXELIOS 1 sequencing platform. | +0.9% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | William Blair and Wedbush reiterate bullish VRDN views; Wedbush raises PT to $43 from $32. | +0.9% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | UBS reiterates VRDN Buy $50 after Lumvoa approval and outlines TAM and launch expectations. | +0.9% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | Citizens reiterates VRDN Market Outperform $35 after FDA approval of Lumvoa. | +0.9% | tweet ↗ |
| 2026-06-28 | @PersimmonTI | +0.00 | Notes GPCR's aleniglipron uses orforglipron base and closely held IP portfolio. | +2.5% | tweet ↗ |
| 2026-06-27 | @PersimmonTI | +0.00 | GPCR CEO claims strong GLP-1 IP moat and licensing leverage. | +2.5% | tweet ↗ |
| 2026-06-23 | @bioinvestor24 | +0.20 | Thinks AMGN needs PRMT5 and questions when TNGX would consider a deal. | +5.3% | tweet ↗ |
| 2026-06-22 | @bioinvestor24 | +0.20 | Questions whether Roche executive hire can fix Sanofi's plight and criticizes prior CEO damage. | +8.0% | tweet ↗ |
| 2026-06-22 | @FierceBiotech | +0.00 | Sanofi R&D chief exiting as new CEO seeks pipeline fix with Roche alum. | +8.0% | tweet ↗ |
| 2026-06-22 | @Quantumup1 | +0.00 | H.C. Wainwright reiterated OCUL Buy and raised PT to $25 from $21. | +8.0% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.